BioNet-Asia’s CEO, Dr Pham Hong Thai provided today an update on the company lead vaccine program in his presentation at BioJapan 2014. Dr Pham said that the current Phase I/II trial in Thailand showed that the vaccine is safe and immunogenic and full results will soon be published in a peer reviewed journal. BioNet Recombinant Acellular Pertussis vaccine will enter clinical Phase II/III in 2015.
Help employers find you! Check out all the jobs and post your resume.
